REDWOOD CITY, Calif., May 23, 2018 - Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of peripheral artery disease.

The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

Two hospitals in East Africa have announced participation in the American College of Cardiology’s CathPCI registry, which aims to assess treatments and outcomes related to cardiac catheterization and percutaneous coronary interventions (PCIs).

PARIS, May 22, 2018 — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests.

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

New research from Florida State University suggests depression screening in patients with coronary artery disease (CAD) is especially crucial, because those individuals tend to have higher rates of morbidity and mortality.

Pennsylvania-based Geisinger Health System plans to soon offer DNA sequencing to 1,000 patients, with the goal of providing the service to all three million of its patients.

Despite being performed in an older population with more cardiovascular comorbidities, transcatheter aortic valve replacement (TAVR) demonstrated similarly low rates of postoperative stroke and mortality compared with surgical aortic valve replacement (SAVR) in a study of patients with previous strokes.

Although survival after congenital heart surgery is improving, patients who receive procedures for even mild defects have long-term mortality rates at least three times higher than their counterparts in the general population, according to a U.S.-based registry study published in the Journal of the American College of Cardiology.